Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor

ABSTRACT

An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day “nocturnally,” that is in the evening or at night.

RELATED PATENT APPLICATIONS

This application for U.S. patent is a U.S.C., Tide 35, §111(a)application which is a continuation of U.S. patent application, Ser. No.08/368,378 filed Jan. 14,1995, which is a continuation-in-part of U.S.patent application, Ser. No. 08/124,392, filed Sep. 20, 1993.

FIELD OF THE INVENTION

This invention generally relates to compositions of nicotinic aciduseful for treating hyperlipidemia and methods of treatinghyperlipidemia employing such compositions. More particularly, thepresent invention employs a composition of nicotinic acid, derivativesand mixtures thereof, and a swelling agent to form a time releasesustaining composition for nocturnal or evening dosing. Specifically,the present invention employs a composition of nicotinic acid andhydroxypropyl methylcellulose to treat hyperlipidemia in a once per dayoral dosage form given during the evening hours.

BACKGROUND

Nicotinic acid has been used for many years in the treatment ofhyperlipidemia. This compound has long been known to exhibit thebeneficial effects of reducing total cholesterol, low densitylipoproteins or “LDL cholesterol”, triglycerides and apolipoprotein aLp(a)) in the human body, while increasing desirable high densitylipoproteins or “HDL cholesterol”.

Nicotinic acid has normally been administered three times per day aftermeals. This dosing regimen is known to provide a very beneficial effecton blood lipids as discussed in Knopp et a; “Contrasting Effects ofUnmodified and Time-Release Forms of Niacin on Lipoproteins inHyperlipidemic Subjects: Clues to Mechanism of Action of Niacin”;Metabolism 34/7, 1985, page 647. The chief advantage of this profile isthe ability of nicotinic acid to decrease total cholesterol, LDLcholesterol, triglycerides and Lp(a) while increasing HDL particles.While such a regimen does produce beneficial effects, cutaneous flushingand the like still often occurs in the hyperlipidemics to whom thecompound is administered.

In order to avoid or reduce the cutaneous flushing, a number ofmaterials have been suggested for administration with an effectiveantihyperlipidemic amount of nicotinic acid, including guar gum in U.S.Pat. No. 4,965,252, and mineral salts as disclosed in U.S. Pat. No.5,023,245; or inorganic magnesium salts as reported in U.S. Pat. No.4,911,917. These materials have been reported to avoid or reduce thecutaneous flushing side effect commonly associated with nicotinic acidtreatment.

Another method of avoiding or reducing the side effects associated withimmediate release niacin is the use of sustained release formulations.Sustained release formulations are designed to slowly release thecompound from the tablet or capsule. The slow drug release reduces andprolongs blood levels of drug and thus minimizes the side effects.Sustained release formulations of niacin have been developed, such asNICOBID™ capsules (Rhone-Poulenc Rorer), ENDUR-ACIN™ (InnoviteCorporation) and U.S. Pat. No. 5,126,145 which describes a sustainedrelease niacin formulation containing two different types ofhydroxypropyl methylcellulose and a hydrophobic component.

Studies in hyperlipidemic patients have been conducted with a number ofsustained release niacin products. These studies have demonstrated thatthe sustained release products do not have the same advantageous lipidaltering effects as immediate release niacin, and in fact often have aworse side effect profile compared to the immediate release product. Themajor disadvantage of the sustained release formulations, as can be seenin Knopp et al., 1985, is the significantly lower reduction intriglycerides (−2% for the sustained release versus −38% for theimmediate release) and lower increase in HDL cholesterol, represented asHDL₂ particles which are known by the an to be most beneficial (−5% forthe sustained release versus +37% for the immediate release).

Additionally, sustained release niacin formulations have been noted ascausing greater incidences of liver toxicity as described in Henken etal (Am J Med 91:1991 1991) and Dalton et al (Am J Med 93: 102 1992).There is also great concern regarding the potential of theseformulations in disrupting glucose metabolism and uric acid levels.

In a recent edition of the JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION(JAMA), an article appeared which presented research resultsinvestigating the liver toxicity problems associated with a sustainedrelease form of nicotinic acid. “A Comparison of the Efficacy and ToxicEffects of Sustained-vs. Immediate-Release Niacin inHypercholesterolemic Patients”, Mckenney et al., JAMA, Vol. 271, No. 9,Mar. 2, 1994, page 672. The article presented a study of twenty-threepatients. Of that number, 18 or 78 percent were forced to withdrawbecause liver function tests (LFTs) increased indicating potential liverdamage. The conclusion of the authors of that article was that thesustained release form of niacin “should be restricted from use.”

A similar conclusion was reached in an article authored byrepresentatives of the Food and Drug Administration and entitled“Hepatic Toxicity of Unmodified and Time-Release Preparations ofNiacin”, Rader, et al., THE AMERICAN JOURNAL OF MEDICINE, Vol. 92,January 1992, page 77. Because of these studies and similar conclusionsdrawn by other health care professionals, the sustained release forms ofniacin have experienced limited utilization.

Therefore, it can be seen from the scientific literature that there is aneed for development of a sustained release niacin formulation and amethod of delivering said formulation which would provide hyperlipidemicpatients with “balanced lipid alteration”, i.e. reductions in totalcholesterol, LDL cholesterol, triglycerides and Lp(a) as well asincreases in HDL particles, with an acceptable safety profile,especially as regards liver toxicity and effects on glucose metabolismand uric acid levels.

SUMMARY OF THE INVENTION

In brief, the present invention alleviates and overcomes certain of theabove-identified problems and shortcomings of the present state ofnicotinic acid therapy through the discovery of novel nicotinic acidformulations and methods of treatment.

It is therefore an object of the present invention to provide acomposition of nicotinic acid or any compound which is metabolized bythe body to form nicotinic acid for treating hyperlipidemia.

It is another object of the present invention to provide a compositionas above, which has a time release sustaining characteristic.

It is yet another object of the present invention to provide a methodfor employing a composition as above, for treating hyperlipidemia, whichresults in little or no liver damage.

At least one or more of the foregoing objects, together with theadvantages thereof over the known art relating to the treatment ofhyperlipidemia, which shall become apparent from the specification whichfollows, are accomplished by the invention as hereinafter described andclaimed.

In general the present invention provides an improved antihyperlipidemiacomposition of the oral type employing an effective antihyperlipidemicamount of nicotinic acid, wherein the improvement comprises compoundingthe nicotinic acid with from about 5% to about 50% parts by weight ofhydroxypropyl methylcellulose per hundred parts by weight of tablet orformulation.

The present invention also provides an orally administeredantihyperlipidemia composition which comprises from about 30% to about90% parts by weight of nicotinic acid; and, from about 5% to about 50%parts by weight of hydroxypropyl methylcellulose.

The present invention also includes a method of treating hyperlipidemiain a hyperlipidemic. The method comprises the steps of forming acomposition which comprises an effective antihyperlipidemic amount ofnicotinic acid and an amount of excipients to provide sustained releaseof drug. The method also includes the step of orally administering thecomposition to the hyperlipidemic nocturnally.

A method of treating hyperlipidemia in a hyperlipidemic according to theinvention comprises dosing the hyperlipidemic with an effectiveantihyperlipidemic amount of nicotinic acid or compound metabolized tonicotinic acid by the body. The dose is given once per day in theevening or at night, combined with a pharmaceutically acceptable carrierto produce a significant reduction in total and LDL cholesterol, as wellas a significant reduction in triglycerides and Lp(a), with asignificant increase in HDL cholesterol.

The above features and advantages of the present invention will bebetter understood with reference to the following detailed descriptionand examples. It should also be understood that the particular methodsand formulations illustrating the present invention are exemplary onlyand not to be regarded as limitations of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

By way of illustrating and providing a more complete appreciation of thepresent invention and many of the attendant advantages thereof, thefollowing detailed description and examples are given concerning thenovel methods and formulations.

The present invention employs nicotinic acid or a compound other thannicotinic acid itself which the body metabolizes into nicotinic acid,thus producing the same effect as described herein. The other compoundsspecifically include, but are not limited to the following: nicotinylalcohol tartrate, d-glucitol hexanicotinate, aluminum nicotinate,niceritrol and d,1-alpha-tocopheryl nicotinate. Each such compound willbe collectively referred to hereinbelow by “nicotinic acid.”

As stated hereinabove, nicotinic acid has been employed in the past forthe treatment of hyperlipidemia, which condition is characterized by thepresence of excess fats such as cholesterol and triglycerides, in theblood stream. According to the present invention, a sustained releasecomposition of nicotinic acid is prepared as an example. By “sustainedrelease” it is understood to mean a composition which when orallyadministered to a patient to be treated, the active ingredient will bereleased for absorption into the blood stream over a period of time. Forexample, it is preferred that in a dosage of about 1500 milligramshereinafter “mgs”) of nicotinic acid, approximately 400 percent of thenicotinic acid will be released to the blood stream in about 4 to about24 hours.

The specific sustained release composition according to the presentinvention employs an effective antihyperlipidemic amount of nicotinicacid. By “effective antihyperlipidemic amount” it is understood to meanan amount which when orally administered to a patient to be treated,will have a beneficial effect upon the physiology of the patient, toinclude at least some lowering of total cholesterol, LDL cholesterol,triglycerides and Lp(a) and at least some increase in HDL cholesterol inthe patient's blood stream. An exemplary effective antihyperlipidemicamount of nicotinic acid would be from about 250 mgs to about 3000 mgsof nicotinic acid to be administered according to the invention as willbe more fully described hereinbelow. This amount will vary dependentupon a number of variables, including the psychological needs of thepatient to be treated.

Preferably, there is also included in the sustained release compositionaccording to the present invention, a swelling agent which is compoundedwith the nicotinic acid, such that when the composition is orallyadministered to the patient, the swelling agent will swell over time inthe patient's gastrointestinal tract and release the active nicotinicacid, or a compound which produces nicotinic acid into thegastrointestinal system for absorption into the blood stream, over aperiod of time. As is known in the art, such swelling agents and amountsthereof, may be preselected in order to control the time release of theactive ingredient. Such swelling agents include, but are not limited to,polymers such as sodium carboxymethylcellulose and ethylcellulose andwaxes such as bees wax and natural materials such as gums and gelatinsor mixtures of any of the above. Because the amount of the swellingagent will vary depending upon the nature of the agent, the time releaseneeds of the patient and the like, it is preferred to employ amounts ofthe agent which will accomplish the objects of the invention.

An exemplary and preferred swelling agent is hydroxypropylmethylcellulose, in an amount ranging from about 5% to about 50% partsby weight per 100 parts by weight of tablet or formulation. Thepreferred example will ensure a sustained time release over a period ofapproximately 4-24 hours as demonstrated by in vitro dissolutiontechniques known to the art.

A binder may also be employed in the present compositions. While anyknown binding material is useful in the present invention, it ispreferred to employ a material such as one or more of a group ofpolymers having the repeating unit of 1-ethenyl-2-pyrrolidinone. Thesepolymers generally have molecular weights of between about. 10,000 and700,000. and are also known as “povidone”.

Amounts of the binder material will of course, vary depending upon thenature of the binder and the amount of other ingredients of thecomposition. An exemplary amount of povidone in the present compositionswould be from about 1% to about 5% by weight of povidone per 400 partsby weight of the total formulation.

Processing aids such as lubricants, including stearic acid, may also beemployed, as is known in the art. An exemplary amount of stearic acid inthe present compositions would be from about 0.5% to about 2.0% byweight per 100 parts by weight of tablet or formulation.

Examples of various embodiments of the present invention will now befurther illustrated with reference to the following examples.

General Experimental

In order to demonstrate the effectiveness of the compositions and methodof the present invention over known antihyperlipidemia compositions andmethods heretofore known in the art, a number of substantially identicalcomposition were prepared according to the disclosure hereinabove. Thecomposition ingredients and amounts are listed in TABLE IA hereinbelow.TABLE IA Test Tablet Composition Ingredient 375 mg 500 mg 750 mgNicotinic Acid 375.0 500.0 750.0 Hyroxypropyl methylcellulose 188.7203.0 204.7 Povidone 12.9 17.2 25.9 Stearic Acid 5.8 7.3 9.9 TOTAL 582.4mg 727.5 mg 990.5 mg

The ingredients were compounded together to form a tablet. Morespecifically, NIASPAN® once-daily tablets in accordance with the presentinvention utilize a hydrophilic matrix controlled drug delivery system.This is a dynamic system composed of polymer wetting, polymer hydrationand polymer disintegration/dissolution. The mechanism by which drugrelease is controlled depends on, for example, initial polymer wetting,expansion of the gel layer, tablet erosion and niacin solubility. Afterinitial wetting, the hydrophilic polymer starts to partially hydrate,forming a gel layer. As water permeates into the tablet increasing thethickness of the gel layer, drug diffuses out of the gel layer. As theouter layer of the tablet becomes fully hydrated it erodes. It isbelieved that this erosion results in additional drug release. Thecontrolled release from this matrix delivery system can be modifieddepending on the type and molecular weight of hydrophilic polymer used.

A NIASPAN® formulation consists of Niacin, METHOCEL® E10M Premium,Povidone K90 and HYSTRENE® 5016 (stearic acid). METHOCEL® E10M Premiumis utilized as a controlled-release agent in the NIASPAN® formulation.METHOCEL® is a partly O-methylated and O-(2-hydroxypropylated) celluloseand is available in several grades which vary in terms of viscosity anddegree of substitution. METHOCEL® is manufactured by Dow Chemical.

Povidone K90 is employed as a granulating/binding agent in a NIASPAN®formulation. Povidone is a synthetic polymer consisting of linear1-vinyl-2-pyrrolidone groups, the degree of polymerization of whichresults in polymers of various molecular weights, or as indicated above.It is characterized by its viscosity in aqueous solution, relative tothat of water, expressed as a I(-value, ranging from 10-120. PovidoneK90 has an approximate molecular weight of 1,000,000. Povidone is ahygroscopic, water soluble material. Povidone K90 present in a NIASPAN®formulation is manufactured by ISP (International Specialty Products).HYSTRENE® 5016 is utilized as an external lubricant in the NIASPAN®formulation. HYSTRENE® 5016 is a mixture of stearic acid and palmiticacid. The content of stearic acid is not less than about 40.0% and thesum of the two acids is not less than about 90.0%. HYSTRENE® 5016 ismanufactured by Witco. Refer to Table IB for NIASPAN® formulationdetails.

Qualitatively, the four tablet strength formulations are identical. Themajor component of each formulation is a granulated mixture of Niacin,METHOCEL® E10

M and Povidone K90. The granulation process improves compressionproperties. TABLE IB NIASPAN ® Product 375 mg 500 mg 750 mg 1000 mgFormulation, %/Tablet Tablets Tablets Tablets Tablets Niacin 64.4 70.577.4 83.1 METHOCEL ® E10M 7.4 8.1 8.9 9.5 Premium (Intragranular) 2.22.4 2.7 2.9 Povidone K90 METHOCEL ® E10M Premium 25.0 18.0 10.0 3.5(Extragranular) HYSTRENE ® 5016 1.0 1.0 1.0 1.0 (Stearic Acid) Tabletweight, mg 582.5 709.5 968.6 1203.6

NIASPAN® formulations are presented in white caplet shape tablets.Caplet dimensions differ with respect to product strength. The 375 mgand 500 mg NIASPAN® tablets are compressed with tooling measuringapproximately 0.687″ in length×0.281″ by width. The length and width ofthe 750 mg and 1000 mg tooling measures approximately 0.750″×0.320″.Target tablet weight and hardness dictate thickness across the fourNIASPAN® products. The production of the NIASPAN® tablets will now bedescribed generally as set forth below.

NIASPAN® Granulation Process Flow Chart Process Raw Materials FlowEquipment NIACIN ® Granulate High shear granulator Povidone K90(Littleford FM130) METHOCEL ® E10M (Intragranular) ↓ Purified Water DryFluid bed drier (Glatt fluid bed drier) ↓ Parcel size Mill reduction(KEMUTEC BETAGRIND ®)

NIASPAN® Granulation Process Description

NIASPAN® granulation raw materials are dispensed and granulated in ahigh shear granulator. The wet granules are sieved into a fluid beddrier and are dried. When the drying process is complete, the granulesare milled. Milling ensures uniform particle size distributionthroughout the NIASPAN® granulation. NIASPAN ® Tablet Process Flow ChartProcess Flow NIASPAN ® Raw Materials Tablet Blend Equipment METHOCEL ®E10M Blend Milled NIASPAN ® Blender (Extragranular) granules withextragranular (Panerson- HYSTRENE ® 5016 METHOCEL ® E10M and Kelley(Stearic acid) HYSTRENE ® 5016 V-Blender) ↓

NIASPAN ® Tablet Manufacture Compress NIASPAN ® Tablet Blend Rotarytablet press

NIASPAN® Tablet Process Description

A NIASPAN® tablet blend is manufactured by blending the NIASPAN®granulation, extragranular METHOCEL® E10M and HYSTRENE® 5016. Thequantities of each NIASPAN® tablet blend component will depend on theparticular NIASPAN® dose being manufactured (refer to Table IB). ANIASPAN® tablet blend is compressed to form NIASPAN® tablets. NIASPAN®tablet physical properties will vary depending on the particularNIASPAN® dose being manufactured.

Production of NIASPAN® tablets will now be discussed in greater detail.The initial stage of manufacturing is the same for all four tabletstrengths of NIASPAN® (375, 500, 750, and 1000 mg). One batch ofNIASPAN® granulation is comprised of four individual 40.0 kg units ofgranulation which are processed separately, but under like conditions.The four individual granulations are sampled and tested individually andsubsequently released for blending. The base granulation is not strengthspecific and may be used to manufacture any tablet strength of NIASPAN®.

The ingredients in the base granulation are set forth in Table IC below:TABLE IC Quantity Quantity per % per per kilogram kilogram 160.00 kggranulation granulation batch Component Function (kg) (%) (kg) NiacinUSP Drug 0.87 87.00 139.20 Substance Povidone USP Binder 0.03 3.00 4.80METHOCEL ® Controlled- 0.10 10.00 16.00 USP, E10M Release Premium CRAgent Grade Purified Granulation 0.00* 0.00* 48.00 Water, Reagent USP*Total 160.00*Purified Water, USP is used as a granulation reagent and does notappear in the finished granulation.

Raw materials are quantatively dispensed into appropriately labeleddouble polyethylene-lined containers using calibrated scales. PurifiedWater, USP is dispensed into an appropriate vessel from which it islater pumped during the wet-massing operation.

A Littleford FM130 granulator is charged with approximately one half ofthe Niacin, USP required for the process unit (˜17.4 kg) followed byabout 4.00kg of METHOCEL®, USP E10M Premium CR Grade; about 1.20 kg ofPovidone, USP; and the balance of the Niacin, SP (˜17.40 kg). The powderbed is dry mixed in the Littleford FM130 granulator, with choppers on,for approximately 1 minute. At the completion of the 1-minute pre-mixcycle, about 12.0±0.05 kg of Purified Water, USP are sprayed onto thepowder bed at a rate of about 2.40±0.24 kg/minute. Immediately followingthe addition of the Purified Water, USP, the unit is granulated forabout 5 minutes.

The granulated unit is discharged into double polyethylene-linedcontainers and then manually loaded into a Glatt bowl while being passedthrough a #4 mesh screen. The Glatt bowl is loaded into a Glatt TFO-60fluid-bed drier with an inlet air temperature setting of about 70° C.±5°C. The unit is dried until a moisture level of ≦1.0% is obtained asdetermined using a COMPUTRACT® Moisture Analyzer, model MA5A. The driedgranulation is discharged into appropriately labeled, doublepolyethylene-lined drums and reconciled.

The dried and reconciled granulation is passed through a KEMUTECBETAGRIND® mill equipped with a 1.5 mm screen and running atapproximately 1500 RPM. The milled granulation is collected intoappropriately labeled, double polyethylene-lined drums and reconciled.The milled granulation is sampled and tested by Quality Control andreleased prior to further processing.

The released granulation units are charged to a Patterson-Kelly 20 ft³V-blender after which they are blended together for about 10±1 minutesand then discharged to appropriately labeled, double polyethylene-linedcontainers.

As stated above, NIASPAN® tablets are formulated from a commongranulation which is blended with appropriate quantities of METHOCEL®,USP E10M Premium CR Grade and Stearic Acid, NF to achieve the finaldosage formulation. Tables IA and IB describe the formulation for eachNIASPAN® tablet strength,375 mg, 500 mg, 750 mg, and 1000 mg,respectively.

Two study groups consisting of eleven and fourteen patients each wereformed. Blood samples were taken from the patients, and tested for totalcholesterol, LDL cholesterol, triglycerides and HDL cholesterol toestablish baseline levels from which fluctuations in these lipids couldbe compared. The patients were then placed upon a regimen of the abovediscussed tablets, totaling approximately 1500 mg of nicotinic acid,once per day before going to bed. After eight weeks of this regimen, thepatients were again tested for lipid profiles. The results of the testsconducted at eight weeks, showing the changes in the lipid profiles as apercentage change from the baseline, are reported in the tablehereinbelow. Positive numbers reflect percentage increases and negativenumbers reflect percentage decreases in this table. TABLE II PatientStudy Lipid Profile Data Pt. No. Total-C LDL-C ApoB Trigs HDL-C HDL₂-CLp(a) GROUP A 1 −8.2 −12.0 NA −17.3 22.0 NA NA 2 −5.9 −27.0 NA −28.765.0 NA NA 3 −15.1 −13.0 NA −22.0 −9.1 NA NA 4 −3.3 −10.0 NA 61.6 3.8 NANA 5 −16.5 −17.7 NA −28.8 11.1 NA NA 6 −12.4 −25.9 NA −42.0 51.6 NA NA 7−24.2 −31.4 NA −39.4 12.5 NA NA 8 −6.7 −7.4 NA −42.4 18.8 NA NA 9 4.51.1 NA 7.2 9.2 NA NA 10  2.8 −0.2 NA −2.7 22.9 NA NA 11  −13.0 −9.4 NA−54.0 44.3 NA NA Mean −8.9 −13.9 NA −18.9 23.0 NA NA p-Value 0.00040.0001 0.0371 0.0068 GROUP B 1 −19.2 −27.1 −24.4 −33.4 20.0 22.3 −81.9 2−32.2 −35.7 −28.0 −60.4 4.3 3.2 −25.3 3 −21.4 −33.6 −35.6 −33.4 30.438.6 −17.4   4− −19.9 −24.6 −15.1 −20.8 9.6 16.1 −27.0 5 −3.3 −2.1 −29.4−41.1 5.8 2.4 −22.4 6 PATIENT WITHDREW FROM STUDY 7 23.1 −32.6 −42.6−58.6 49.2 68.9 −14.3 8 24.8 34.0 −28.4 5.5 6.5 −6.8 NA 9 10.1 12.0−16.8 −11.6 20.7 −12.3 40.6 10  −2.9 −7.7 −28.0 −59.0 53.1 70.5 −41.211  −10.5 −18.8 −25.3 −53.4 31.8 39.7 NA 12  −20.0 −30.8 −30.4 11.7 21.125.0 −28.4 13  17.4 16.8 −17.5 −17.5 51.3 51.9 38.5 14  −9.4 −16.6 −32.0−46.9 52.3 67.6 17.6 Mean −8.7 −12.8 −32.2 −27.2 25.3 30.1 −17.9 p-Value0.0002 <0.0001 0.0001 <0.001 <0.0001 0.0002 <0.0188 Combined −8.7 −13.3Gp B −26.1 25.3 Gp B Gp B p-Value 0.0002 <0.0001 only <.0001 <0.0001only only

The data reported in TABLE II shows that the LDL levels in the Group Apatients had a mean decrease of −13.9% and triglyceride decrease of−18.9% HDL₂ cholesterol levels, the beneficial cholesterol, were raisedby 23.0% in this Group. Similar results were obtained with the Group Bpatients. These studies demonstrate that dosing the sustained releaseformulation during the evening hours or at night provides reductions inLDL cholesterol levels equal to immediate release niacin on a milligramper milligram basis, but superior reductions in triglyceride reductionswhen compared to sustained release formulations dosed during daytimehours on a milligram per milligram basis. Additionally, the increases inHDL cholesterol obtained from dosing the sustained release formulationduring the evening or at night were +23.0% for one group and +25.3 % forthe other group. Dosing during the evening therefore provides reductionin LDL cholesterol plus significant decreases in triglycerides andincreases in HDL cholesterol with once-a-day dosing.

Groups A and B were also tested for liver enzymes (AST, ALT and AlkalinePhosphatase), uric acid and fasting glucose levels at the start of thestudy described hereinabove (to form a basline) and at two, four andeight week intervals. The results of these tests are listed in TABLESIII-VII hereinbelow. TABLE III THE EFFECT OF NIASPAN ® THERAPY ON AST(SGOT) LEVELS (U/L) (1500 mgs dosed once-a-day at night) (n = 28) Weeksof Therapy with NIASPAN ® Pt# Baseline 2 Wks. 4 Wks. 8 Wks. ReferenceRange GROUP A 1 28 29 25 24 0-50 2 24 25 24 26 0-50 3 17 18 22 21 0-50 414 16 15 17 0-50 5 22 NA 32 52 0-50 6 21 17 17 14 0-50 7 17 17 14 180-50 8 20 21 22 22 0-50 9 16 16 17 20 0-50 10  18 21 21 25 0-50 11  2121 22 21 0-50 GROUP B 1 23 25 38 33 0-50 2 20 20 21 21 0-50 3 15 20 1819 0-50 4 25 22 25 26 0-50 5 23 21 17 18 0-50 6 PATIENT WITHDREW DUE TOFLUSHING 7 21 18 18 19 0-50 8 18 19 18 19 0-50 9 15 16 18 15 0-50 10  1615 19 28 0-50 11  20 22 24 28 0-50 12  23 25 28 22 0-50 13  20 15 20 190-50 14  18 25 20 18 0-50 Combined 19.8 20.4 20.8 21.1 Mean Change +3.0%+5.1% +6.6% From BaselineLevel of Significance: p = 0.4141

TABLE IV THE EFFECT OF NIASPAN ® THERAPY ON ALT (SGPT) LEVELS (U/L)(1500 mgs dosed once-a-day at night) (n = 28) Weeks Of Therapy WithNIASPAN ® Pt# Baseline 2 Wks. 4 Wks. 8 Wks. ReferenceRange GROUP A 1 3228 39 30 0-55 2 24 25 23 26 0-55 3 18 23 30 30 0-55 4 7 13 14 14 0-55 514 NA 43 46 0-55 6 22 11 14 10 0-55 7 9 7 11 7 0-55 8 16 18 23 21 0-55 914 17 20 14 0-55 10  14 15 17 19 0-55 11  18 18 20 16 0-55 GROUP B 1 1617 27 29 0-55 2 16 14 15 22 0-55 3 13 21 13 16 0-55 4 23 20 26 17 0-55 521 23 17 15 0-55 6 PATIENT WITHDREW DUE TO FLUSHING 7 21 16 18 21 0-55 818 20 17 18 0-55 9 11 5 11 8 0-55 10  8 10 14 17 0-55 11  17 12 18 160-55 12  14 18 20 16 0-55 13  14 NA 11 10 0-55 14  23 23 19 19 0-55Combined 17.7 17.5 19.3 18.2 Mean Change −1.1% 9.0% +2.8% From BaselineLevel of Significance: p = 0.3424

TABLE V THE EFFECT OF NIASPAN ® THERAPY ON ALKALINE PHOSPHATASE LEVELS(U/L) (1500 mgs dosed once-a-day at night) (n = 28) Weeks Of TherapyWith NIASPAN ® Pt# Baseline 2 Wks. 4 Wks. 8 Wks. Reference Range GROUP A1 52 56 57 55 20-140 2 103 100 89 102 20-140 3 54 45 53 51 20-140 4 7068 71 91 20-140 5 77 NA 74 81 20-140 6 55 48 49 51 20-140 7 72 71 79 7520-140 8 55 49 47 50 20-140 9 53 55 56 45 20-140 10  74 73 75 75 20-14011  18 18 20 16 20-140 GROUP B 1 73 67 89 95 20-140 2 82 64 72 71 20-1403 73 69 72 82 20-140 4 37 36 37 38 20-140 5 65 53 54 61 20-140 6 PATIENTWITHDREW DUE TO FLUSHING 7 64 58 58 58 20-140 8 79 78 65 73 20-140 9 9492 103 93 20-140 10  69 67 70 65 20-140 11  59 67 63 72 20-140 12  65 5959 63 20-140 13  64 68 66 64 20-140 14  72 61 59 64 20-140 Combined 66.561.5 63.3 65.8 Mean Change −6.1% −3.4% +0.005% From BaselineLevel of Significance: p == 0.0236

TABLE VI THE EFFECT OF NIASPAN ® THERAPY ON URIC ACID LEVELS (mg/dL)(1500 mgs dosed once-a-day at night) (n = 28) Weeks Of Therapy WithNIASPAN ® Pt# Baseline 2 Wks. 4 Wks. 8 Wks. ReferenceRange GROUP A 1 5.25.0 4.8 4.3 4.0-8.5 2 4.0 4.6 4.5 6.2 2.5-7.5 3 6.3 7.0 6.5 6.2 4.0-8.54 3.1 4.6 4.2 3.8 2.5-7.5 5 3.4 NA 3.3 4.2 2.5-7.5 6 6.6 5.5 5.6 4.74.0-8.5 7 3.8 4.5 4.3 4.9 2.5-7.5 8 4.4 3.8 5.1 4.5 2.5-7.5 9 3.9 4.54.6 3.5 2.5-7.5 10  2.6 2.9 2.8 2.7 2.5-7.5 11  4.7 5.5 5.2 5.3 2.5-7.5GROUP B 1 3.7 4.2 4.7 3.5 2.5-7.5 2 2.8 3.5 3.6 2.3 4.0-8.5 3 4.2 5.35.5 5.3 2.5-7.5 4 4.7 3.9 5.1 3.6 4.0-8.5 5 3.7 4.1 4.1 3.8 2.5-7.5 6PATIENT WITHDREW DUE TO FLUSHING 7 5.8 6.6 6.6 6.8 2.5-7.5 8 4.7 4.3 5.45.6 2.5-7.5 9 3.7 4.6 5.1 3.8 2.5-7.5 10  4.2 5.0 4.4 8.5 2.5-7.5 11 1.9 3.0 2.8 5.0 2.5-7.5 12  5.6 5.4 6.2 5.6 4.0-8.5 13  4.2 4.6 4.6 5.32.5-7.5 14  5.5 5.4 6.1 5.3 2.5-7.5 Combined 4.54 4.82 4.92 4.86 *p =0.3450 Mean Change +6.2% +8.4% +7.0% From Baseline*Level of Significance: p == 0.3450

TABLE VIII THE EFFECT OF NIASPAN ® THERAPY ON FASTING GLUCOSE LEVELS(mg/dL) (1500 mgs dosed once-a-day at night) (n = 28) Weeks Of TherapyWith NIASPAN ® Pt# Baseline 2 Wks. 4 Wks. 8 Wks. Reference Range GROUP A1 114 122 123 110 70-115 2 101 105 107 101 80-125 3 99 98 109 103 70-1154 100 118 94 94 80-125 5 89 NA 82 103 80-125 6 97 103 94 107 70-115 7 85107 100 94 80-125 8 98 107 103 101 80-125 9 97 97 100 110 80-125 10  94101 111 97 70-115 11  102 103 95 95 80-125 GROUP B 1 101 97 83 99 70-1152 90 95 96 89 80-125 3 96 98 95 97 70-115 4 116 139 113 125 80-125 5 8892 91 95 70-115 6 PATIENT WITHDREW DUE TO FLUSHING 7 106 114 118 11770-115 8 95 106 106 108 70-115 9 81 92 84 92 70-115 10  108 117 122 10570-115 11  85 106 106 108 70-115 12  92 89 101 86 80-125 13  99 105 94100 70-125 14  100 108 84 107 70-125 Combined 98.4 105.8 101.6 102.3Mean Change +7.5% +3.3% +4.0% From BaselineLevel of Significance : p = 0.0021

TABLE VIII A Comparison of Changes in Liver Function Tests DOSE: 0 5001000 1500 2000 2500 3000 TOTAL McKenney SR^(b) Niacin^(a) AST 23.8 27.940.4 36.6 56.5 NA 97 % — 117 170 154 237 NA 408 Invention Dosage^(c) AST24.3 NA 23.7 27.5 26.6 27.6 27.8 % — NA 98 113 109 114 114 McKenney SRNiacin ALT 25.6 29.5 36.3 39.0 59.1 NA 100.0 % — 115 142 152 231 NA 391Invention Dosage ALT 21.4 NA 18.7 22.6 21.3 22.4 21.8 % — NA 87 106 100105 102 McKenney SR Niacin ALK 95   95 106 105 136 NA 135 % — 100 112111 143 NA 142 Invention Dosage ALK 74.7 NA 73.9 76.1 73.4 76.7 78 % —NA 99 102 98 103 104 McKenney SR Niacin Drop — 0 2 2 7 NA 7 18 n — — — —— — — 23 % — 0 9 9 30 NA 30 78 Invention Dosage Drop — — 0 0 0 0 0 0 n —— 26 67 97 35 15 240 % — — 0 0 0 0 0 0 1 year — — 15 46 77 31 15 184 1year — — 58 69 79 89 100 77^(a)Dosed twice-per-day as described in “A Comparison of the Efficacyand Toxic Effects of Sustained - vs Immediate Release Niacin inHypercholesterolemic Patients” by McKenney et al. Journal of theAmerican Medial Association. Mar. 2, 1994; 271, No. 9, pages 672-677.^(b)SR is “sustained release”^(c)Dosed once-per-day at night

In order to provide a comparison between the state of the art prior tothe present invention, and in order to quantify the magnitude of theimprovement that the invention provides over the prior art, anotherstudy was conducted. This study included 240 patients dosed according tothe present invention as described hereinabove. Compared to this groupwas the group of patients studied by McKenney et al., as reportedhereinabove. The results of this study are reported in TABLE VIIIhereinbelow.

The results of the comparison of the studies reported in TABLE VII showthat the control group (the McKenney group) had 18 of 23, or 78 percentof the patients therein drop out of the test because of an increase intheir respective liver function tests. The patients withdrew at thedirection of the investigator. In comparison, a group of 240 patientstreated according to the present invention had zero patients drop out,based upon the same criteria for withdrawal. The tests results reportedabove indicate that this sustained release dosage form caused noelevation in liver function tests (i.e., no liver damage), no elevationsin uric acid and only a small, 7.5% increase in fasting glucose levelswhich in fact decreased during continued therapy.

Thus it should be evident that the compositions and method of thepresent invention are highly effective in controlling hyperlipidemia inhyperlipidemics, by reducing the levels of LDL cholesterol, triglycerideand Lp(a) while increasing HDL₂ cholesterol levels. The presentinvention is also demonstrated not to cause elevations in liver functiontests, uric acid or glucose levels for the hyperlipidemics.

Based upon the foregoing disclosure, it should now be apparent that theuse of the compositions and methods described herein will carry out theobjects set forth hereinabove. It is, therefore, to be understood thatany variations in sustained release formulation evident fall within thescope of the claimed invention and thus, the selection of specificcomponent elements can be determined without departing from the spiritof the invention herein disclosed and described. In particular,sustained release excipients, binders and processing aids according tothe present invention are not necessarily limited to those exemplifiedhereinabove. Thus, the scope of the invention shall include allmodifications and variations that my fall within the scope of theattached claims.

1. (canceled)
 2. (canceled)
 3. (canceled)
 4. (canceled)
 5. (canceled) 6.(canceled)
 7. (canceled)
 8. (canceled)
 9. (canceled)
 10. (canceled) 11.(canceled)
 12. (canceled)
 13. A sustained release antihyperlipidemiacomposition comprising: about 500 mg to about 3000 mg of nicotinic acidand a pharmaceutically acceptable carrier, wherein the composition isadministered to a hyperlipidemic after food once per day, and furtherwherein the composition reduces the total cholesterol, LDL cholesterol,triglycerides and Lp(a) of the hyperlipidemic, and further wherein thecomposition significantly increases the HDL cholesterol of thehyperlipidemic.
 14. The composition according to claim 13, wherein thecomposition is dosed with from about 250 parts to about 3000 parts byweight of nicotinic acid.
 15. The composition according to claim 13,wherein the release rate of said nicotinic acid is from about 2.0% perhour to about 25% per hour.
 16. The composition according to claim 13,wherein the nicotinic acid is dosed in the form of a tablet prepared byformulating the nicotinic acid with from about 5% to about 50% parts byweight of hydroxypropyl methylcellulose per 100 parts by weight oftablet.
 17. The composition according to claim 13, wherein the nicotinicacid is dosed in a form of a tablet containing from about 1 to about 4parts by weight binder per 100 parts by weight of tablet.
 18. Thecomposition according to claim 17, wherein the binder is a polymerhaving the repeating polymerization unit 1-ethenyl-2-pyrrolidone. 19.The composition according to claim 13, wherein the nicotinic acid isdosed in a form of a tablet comprising from about 0.5 to about 2.5 partsby weight of a lubricating agent per 100 parts by weight of tablet. 20.The composition according to claim 19, wherein the lubricating agent isselected from the group consisting of stearic acid and magnesiumstearate.
 21. The composition according to claim 13, wherein thenicotinic acid is dosed in the evening or at night.
 22. The compositionof claim 13, wherein the composition contains about 500 mg nicotinicacid.
 23. The composition according to claim 13, wherein the compositioncontains about 750 mg nicotinic acid.
 24. The composition according toclaim 13, wherein the composition contains about 1000 mg nicotinic acid.25. The composition according to claim 13, wherein the compositioncontains about 1500 mg nicotinic acid.
 26. The composition according toclaim 13, wherein the composition contains about 2000 mg nicotinic acid.27. The composition according to claim 13, wherein the compositioncontains about 3000 mg nicotinic acid.
 28. The composition according toclaim 22, wherein the nicotinic acid is dosed in the evening or atnight.
 29. The composition according to claim 23, wherein the nicotinicacid is dosed in the evening or at night.
 30. The composition accordingto claim 24, wherein the nicotinic acid is dosed in the evening or atnight.
 31. The composition according to claim 25, wherein the nicotinicacid is dosed in the evening or at night.
 32. The composition accordingto claim 26, wherein the nicotinic acid is dosed in the evening or atnight.
 33. The composition according to claim 27, wherein the nicotinicacid is dosed in the evening or at night.